Literature DB >> 3826862

Cross protection of mice and swine inoculated with culture filtrate of attenuated Erysipelothrix rhusiopathiae and challenge exposed to strains of various serovars.

T Sawada, T Takahashi.   

Abstract

Mice and swine inoculated subcutaneously with culture filtrate vaccine prepared from acriflavine-fast attenuated Erysipelothrix rhusiopathiae strain Koganei 65-0.15 (serovar 2), were challenge exposed to 20 pathogenic strains of E rhusiopathiae of 18 serovars and type N. Vaccinated mice survived after challenge exposure to serovars 1b, 2, 8 (strain Goda), and type N, but mortality occurred in vaccinated mice challenge exposed to other strains: 20% to 30% mortality in mice challenge exposed to serovars 1a, 11, 12, 15, 16, or 21; 40% to 50% mortality in mice challenge exposed to serovars 4, 5, 6, 7, or 8 (strain 911); and 60% to 80% mortality in mice challenge exposed to serovars 9, 10, 18, or 19. All vaccinated mice died after challenge exposure with strain 2553 (serovar 20). Non-vaccinated control mice died after challenge exposure to all strains. Of 2 vaccinated swine challenge exposed to strain 2553, 1 developed a local urticarial lesion at the site of intradermal exposure. Vaccinated swine challenge exposed to serovars 1a, 1b, 2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 16, 18, 19, 21, or type N did not have clinical signs of acute erysipelas. Nonvaccinated control swine developed acute generalized erysipelas or localized urticarial lesions at the site of intradermal exposure.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3826862

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  6 in total

1.  Immunization with truncated recombinant protein SpaC of Erysipelothrix rhusiopathiae strain 715 serovar 18 confers protective immunity against challenge with various serovars.

Authors:  Ho To; Shuichi Someno; Shinya Nagai; Tomohiro Koyama; Tetsuji Nagano
Journal:  Clin Vaccine Immunol       Date:  2010-10-06

2.  Characterization and identification of a novel candidate vaccine protein through systematic analysis of extracellular proteins of Erysipelothrix rhusiopathiae.

Authors:  Fang Shi; Yohsuke Ogawa; Akiyuki Sano; Tomoyuki Harada; Jiro Hirota; Masahiro Eguchi; Eiji Oishi; Yoshihiro Shimoji
Journal:  Infect Immun       Date:  2013-09-09       Impact factor: 3.441

3.  Immunological characterization of a protective antigen of Erysipelothrix rhusiopathiae: identification of the region responsible for protective immunity.

Authors:  Y Shimoji; Y Mori; V A Fischetti
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

4.  Genetic and antigenic diversity of the surface protective antigen proteins of Erysipelothrix rhusiopathiae.

Authors:  Ho To; Shinya Nagai
Journal:  Clin Vaccine Immunol       Date:  2007-05-02

Review 5.  Erysipelothrix Spp.: Past, Present, and Future Directions in Vaccine Research.

Authors:  Tanja Opriessnig; Taya Forde; Yoshihiro Shimoji
Journal:  Front Vet Sci       Date:  2020-04-15

6.  Genomic and Immunogenic Protein Diversity of Erysipelothrix rhusiopathiae Isolated From Pigs in Great Britain: Implications for Vaccine Protection.

Authors:  Taya L Forde; Nichith Kollanandi Ratheesh; William T Harvey; Jill R Thomson; Susanna Williamson; Roman Biek; Tanja Opriessnig
Journal:  Front Microbiol       Date:  2020-03-13       Impact factor: 5.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.